Histone Deacetylase Inhibitors Market - Top Companies and Manufacturers

In the News

• Bristol Myers Squibb Co. acquired Mirati Therapeutics, Inc. to expand its commercial portfolio by including KRAZATI, a critical drug for the treatment of adult patients with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC). Furthermore, the business aims to strengthen its pipeline of oncology products and are excellent candidate for both single-agent development and combination approaches to guarantee that patients around the world may benefit from Mirati's array of cutting-edge medications.
• Celleron Therapeutics Ltd. partnered with Roche to receive rights to the clinical development, and commercialization of cancer drugs, Emactuzumab, an investigational monoclonal antibody that targets and reduces macrophages in tumor tissue.